Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why [Yahoo! Finance]
Entrada Therapeutics, Inc. (NASDAQ: TRDA) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Entrada Therapeutics, Inc. (NASDAQ: TRDA) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $29.00 price target on the stock.